To compare the efficacy of oral liarozole , the first retinoic acid metabolism-blocking agent ( RAMBA ) to be developed as differentiation therapy for human solid tumors , with that of cyproterone acetate ( CPA ) , an antiandrogen for the treatment of metastatic prostate cancer .
